Teva Pharmaceutical Industries (NYSE:TEVA) Given New $26.00 Price Target at JPMorgan Chase & Co.

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective lifted by JPMorgan Chase & Co. from $23.00 to $26.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts also recently issued reports on TEVA. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 price objective on the stock. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, UBS Group lifted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average price target of $25.57.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $20.01 on Friday. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The stock’s fifty day moving average price is $18.12 and its 200-day moving average price is $16.81. The firm has a market cap of $22.94 billion, a P/E ratio of -125.03, a P/E/G ratio of 1.17 and a beta of 0.71. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm’s revenue for the quarter was up .3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC lifted its holdings in Teva Pharmaceutical Industries by 14.6% in the third quarter. GAMMA Investing LLC now owns 8,344 shares of the company’s stock valued at $169,000 after acquiring an additional 1,062 shares during the period. Texas Permanent School Fund Corp lifted its stake in shares of Teva Pharmaceutical Industries by 9.9% in the 2nd quarter. Texas Permanent School Fund Corp now owns 357,396 shares of the company’s stock valued at $5,990,000 after purchasing an additional 32,047 shares during the period. Osaic Holdings Inc. boosted its holdings in Teva Pharmaceutical Industries by 17.4% during the second quarter. Osaic Holdings Inc. now owns 48,655 shares of the company’s stock worth $815,000 after buying an additional 7,223 shares in the last quarter. Orion Porfolio Solutions LLC increased its holdings in Teva Pharmaceutical Industries by 23.1% in the second quarter. Orion Porfolio Solutions LLC now owns 12,474 shares of the company’s stock valued at $209,000 after buying an additional 2,341 shares in the last quarter. Finally, Marex Group plc acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter worth about $463,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.